These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 16227138)

  • 21. The effects of dobutamine on renal sympathetic activity in human heart failure.
    Al-Hesayen A; Parker JD
    J Cardiovasc Pharmacol; 2008 May; 51(5):434-6. PubMed ID: 18398381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients >70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure.
    Cioffi G; Stefenelli C; Tarantini L; Opasich C
    Am J Cardiol; 2003 Nov; 92(9):1050-6. PubMed ID: 14583355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal effects of human urotensin-II in rats with experimental congestive heart failure.
    Ovcharenko E; Abassi Z; Rubinstein I; Kaballa A; Hoffman A; Winaver J
    Nephrol Dial Transplant; 2006 May; 21(5):1205-11. PubMed ID: 16396970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure.
    Petersson M; Friberg P; Eisenhofer G; Lambert G; Rundqvist B
    Eur Heart J; 2005 May; 26(9):906-13. PubMed ID: 15764611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unloading therapy by intravenous diuretic in chronic heart failure: a double-edged weapon?
    De Vecchis R; Ciccarelli A; Pucciarelli A
    J Cardiovasc Med (Hagerstown); 2010 Aug; 11(8):571-4. PubMed ID: 20588135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intravenous nitroglycerin on hemodynamics in infants and children with congestive heart failure.
    Zeng H; Sun L; Li W; Du J
    Chin Med J (Engl); 2000 Apr; 113(4):328-31. PubMed ID: 11775229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure.
    Kasama S; Toyama T; Kumakura H; Takayama Y; Ishikawa T; Ichikawa S; Suzuki T; Kurabayashi M
    J Nucl Med; 2004 Jul; 45(7):1108-13. PubMed ID: 15235055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effects of nesiritide and nitroglycerin on renal function, and incidence of renal injury by traditional and RIFLE criteria in acute heart failure.
    Ng TM; Ackerbauer KA; Hyderi AF; Hshieh S; Elkayam U
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):79-85. PubMed ID: 21536855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure.
    den Uil CA; Caliskan K; Lagrand WK; van der Ent M; Jewbali LS; van Kuijk JP; Spronk PE; Simoons ML
    Intensive Care Med; 2009 Nov; 35(11):1893-9. PubMed ID: 19639300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcatheter aortic valve implantation reduces sympathetic activity and normalizes arterial spontaneous baroreflex in patients with aortic stenosis.
    Dumonteil N; Vaccaro A; Despas F; Labrunee M; Marcheix B; Lambert E; Esler M; Carrie D; Senard JM; Galinier M; Pathak A
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1195-202. PubMed ID: 24139928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of clonidine on renal sympathetic nerve activity, natriuresis and diuresis in chronic congestive heart failure rats.
    Feng QP; Carlsson S; Thorén P; Hedner T
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1129-35. PubMed ID: 1534840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiorenal anemia syndrome in chronic heart failure contributes to increased sympathetic nerve activity.
    Franchitto N; Despas F; Labrunee M; Vaccaro A; Lambert E; Lambert G; Galinier M; Senard JM; Pathak A
    Int J Cardiol; 2013 Oct; 168(3):2352-7. PubMed ID: 23415171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Forearm vasoconstriction during dynamic leg exercise in patients with chronic heart failure.
    Atherton JJ; Dryburgh LG; Thomson HL; Moore TD; Wright KN; Muehle GW; Fitzpatrick LE; Frenneaux MP
    Heart Vessels; 1998; 13(6):278-89. PubMed ID: 10651170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
    Kasama S; Toyama T; Sumino H; Kumakura H; Takayama Y; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
    Int J Cardiol; 2013 Jul; 167(1):244-9. PubMed ID: 22245478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired baroreceptor control of renal sympathetic activity in human chronic heart failure.
    Al-Hesayen A; Parker JD
    Circulation; 2004 Jun; 109(23):2862-5. PubMed ID: 15173026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hemodynamic response to high-dose nitroglycerin infusion in patients with severe heart failure after pretreatment and clinical stabilization].
    Faggiano P; Rusconi C
    G Ital Cardiol; 1991 Nov; 21(11):1195-202. PubMed ID: 1809623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
    Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S
    Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure.
    Cohen-Solal A; Rouzet F; Berdeaux A; Le Guludec D; Abergel E; Syrota A; Merlet P
    J Nucl Med; 2005 Nov; 46(11):1796-803. PubMed ID: 16269592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of neuropeptide Y in renal sympathetic vasoconstriction: studies in normal and congestive heart failure rats.
    DiBona GF; Sawin LL
    J Lab Clin Med; 2001 Aug; 138(2):119-29. PubMed ID: 11477379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
    Udelson JE; Orlandi C; Ouyang J; Krasa H; Zimmer CA; Frivold G; Haught WH; Meymandi S; Macarie C; Raef D; Wedge P; Konstam MA; Gheorghiade M
    J Am Coll Cardiol; 2008 Nov; 52(19):1540-5. PubMed ID: 19007589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.